Article
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Feb 2008
MacDonald Tobey J, Stewart Clinton F, Kocak Mehmet, Goldman Stewart, Ellenbogen Richard G, Phillips Peter, Lafond Deborah, Poussaint Tina Young, Kieran Mark W, Boyett James M, Kun Larry E
Abstract excerpt
PURPOSE: A phase I trial of the antiangiogenesis agent cilengitide (EMD 121974), an alpha v beta 3,5 integrin antagonist, was performed to estimate the maximum-tolerated dose (MTD) and describe dose-limiting toxicities (DLTs) and the incidence and severity of other toxicities when administered to children with refractory brain tumors. PATIENTS AND METHODS: Thirty-one assessable patients received intravenous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.